Inmune Bio (INMB) EBIT (2018 - 2026)

Inmune Bio has disclosed EBIT across 9 years of filings, most recently posting -$1.5 million for Q2 2026.

• In Q2 2026, EBIT rose 93.99% year-over-year to -$1.5 million; the TTM figure through Jun 2026 stood at -$20.2 million (up 64.08% YoY), while the FY2025 annual figure was -$47.4 million, down 11.14% from the prior year.
• EBIT came in at -$1.5 million for Q2 2026 at Inmune Bio, up from -$5.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$1.5 million in Q2 2026 to a low of -$24.6 million in Q2 2025.
• Average EBIT over 5 years is -$8.5 million, with a median of -$7.4 million recorded in 2022.
• Year-over-year, EBIT slumped 149.07% in 2025 and soared 93.99% in 2026.
• Over 5 years, EBIT stood at -$5.6 million in 2022, then plunged by 48.51% to -$8.4 million in 2023, then dropped by 12.98% to -$9.5 million in 2024, then surged by 42.18% to -$5.5 million in 2025, then jumped by 73.04% to -$1.5 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$1.5 million in Q2 2026, -$5.8 million in Q1 2026, and -$5.5 million in Q4 2025.